Somatropin

Somatropin is recombinant human growth hormone: a 191-amino-acid polypeptide of molecular weight 22,124 daltons, expressed in Escherichia coli, with an amino acid sequence identical to growth hormone of human pituitary origin. It replaces endogenous growth hormone rather than stimulating the pituitary to release more.

Its effect on skeletal growth is largely indirect. It binds growth hormone receptors on target tissues and stimulates hepatic production of insulin-like growth factor I (IGF-I), which drives proliferation of chondrocytes at the epiphyseal growth plates. Linear growth is possible only while the epiphyses remain open; once they close, somatropin can no longer increase height, which is why closed epiphyses are a contraindication.

Somatropin also acts on metabolism independently of linear growth. Labeled pharmacology spans protein, carbohydrate, lipid and mineral metabolism: nitrogen retention and protein synthesis, increased lipolysis, sodium and water retention expanding extracellular fluid volume, and antagonism of insulin action, which can raise blood glucose.

In children, evidence varies sharply by indication. Pediatric Endocrine Society guidance is deliberately conservative, separating severe growth hormone or IGF-I deficiency, where restoring hormonal normalcy is well supported, from treatment of otherwise healthy short children. For idiopathic short stature, a meta-analysis of 21 studies found treated patients exceeded untreated controls in adult height by 5.3 cm (95% CI 3.4-7) in males and 4.7 cm (95% CI 3.1-6.3) in females.

In adults, the Endocrine Society clinical practice guideline reports benefits in body composition, exercise capacity, skeletal integrity and quality of life, concentrated in more severely deficient patients, and characterizes treatment risks as low.

The SAGhE cohort followed 24,232 patients treated in childhood across eight European countries for more than 400,000 patient-years. All-cause mortality tracked the underlying diagnosis rather than the drug: not significantly increased in isolated growth hormone deficiency or idiopathic short stature (SMR 1.1, 95% CI 0.9-1.3), increased in those born small for gestational age (SMR 1.5, 1.1-1.9), and higher in moderate-risk (SMR 3.8) and high-risk (SMR 17.1) groups whose conditions carry their own mortality. Mortality was not dose-associated. A meta-analysis of 24 articles covering 254,776 people found no significant association with all-cause mortality (SMR 1.28, 0.58-2.84) or cancer incidence, but did find increased second-neoplasm risk (RR 1.77, 1.33-2.35).

Typical dosage: 0.16-0.24 mg/kg/week (pediatric growth hormone deficiency); about 0.2 mg/day (adult growth hormone deficiency) (daily subcutaneous injection).

Dosing is set by indication in the approved labeling and is weight-based in children. Representative Genotropin dosing:

• Pediatric growth hormone deficiency: 0.16-0.24 mg/kg/week • Prader-Willi syndrome: 0.24 mg/kg/week • Turner syndrome: 0.33 mg/kg/week • Small for gestational age: up to 0.48 mg/kg/week • Idiopathic short stature: up to 0.47 mg/kg/week • Adult growth hormone deficiency, non-weight-based: about 0.2 mg/day, range 0.15-0.30 mg/day • Adult growth hormone deficiency, weight-based: 0.04-0.08 mg/kg/week

The weekly pediatric total is divided into daily subcutaneous injections. Adult regimens generally start low and are titrated against clinical response, IGF-I concentrations and side effects, since fluid-retention effects are dose-related and more pronounced in older and heavier patients. Dosing differs between brands, and long-acting weekly products follow entirely different schedules; the specific product's labeling governs.

Somatropin is a prescription-only biologic requiring diagnosis, specialist supervision and laboratory monitoring. This section is educational information about what the labeling reports, not medical advice.

Somatropin is prescribed as monotherapy for its approved indications. The meaningful interactions are with hormone replacement already in place, not other growth-promoting agents.

• Glucocorticoids: labeling directs monitoring of adrenal status, and replacement may need adjustment during treatment • Thyroid hormone: hypothyroidism may first become apparent or worsen, so thyroid function is monitored • Insulin and other antidiabetic therapy: somatropin antagonizes insulin action and can raise glucose

Combining somatropin with growth hormone secretagogues such as Sermorelin or Tesamorelin is not a labeled or evidence-supported strategy, and no controlled trials of such combinations appear among the sources catalogued here. The approaches are mechanistically redundant: secretagogues prompt pituitary release of endogenous growth hormone, whereas somatropin supplies the hormone directly.

Somatropin is approved by the U.S. Food and Drug Administration for one or more labeled indications. Approval covers only the labeled indication, population and dosing. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Fluid retention, edema, arthralgia and carpal tunnel syndrome are common in adults. Labeled warnings include glucose intolerance and new-onset diabetes, intracranial hypertension, slipped capital femoral epiphysis and scoliosis progression in children, hypothyroidism, hypoadrenalism, pancreatitis and hypersensitivity reactions.

Somatropin has a characterized safety profile documented in approved labeling.

Contraindications: acute critical illness, where increased mortality has been reported; active malignancy; active proliferative or severe non-proliferative diabetic retinopathy; closed epiphyses when used for growth promotion; hypersensitivity to somatropin or excipients; and Prader-Willi syndrome with severe obesity, upper airway obstruction, sleep apnea or respiratory impairment, in which fatalities have been reported.

Labeled warnings include:

• Glucose intolerance and new-onset type 2 diabetes; glucose monitoring is required • Intracranial hypertension, which may develop within 8 weeks of starting treatment • Slipped capital femoral epiphysis in children with hip or knee pain, and scoliosis progression • Fluid retention as edema, arthralgia and carpal tunnel syndrome, common in adults • Hypoadrenalism and hypothyroidism, which may become evident or worsen • Increased second-neoplasm risk, particularly meningioma, in survivors of childhood cancer • Pancreatitis, and severe hypersensitivity reactions including anaphylaxis

Treatment requires ongoing specialist monitoring.